Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Accounts Payables (2019 - 2025)

Benitec Biopharma has reported Accounts Payables over the past 7 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Accounts Payables at $1.8 million for Q4 2025, down 23.4% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 23.4% YoY), and the annual figure for FY2025 was $1.0 million, down 75.46%.
  • Accounts Payables reached $1.8 million in Q4 2025 per BNTC's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.9 million in Q4 2023 and bottomed at $880000.0 in Q2 2021.
  • Median Accounts Payables over the past 5 years was $2.0 million (2021), compared with a mean of $2.4 million.
  • The largest annual shift saw Accounts Payables soared 448.17% in 2021 before it crashed 75.46% in 2025.
  • Over 5 years, Accounts Payables stood at $1.9 million in 2021, then fell by 5.96% to $1.8 million in 2022, then skyrocketed by 169.78% to $4.9 million in 2023, then plummeted by 51.08% to $2.4 million in 2024, then decreased by 23.4% to $1.8 million in 2025.
  • Business Quant data shows Accounts Payables for BNTC at $1.8 million in Q4 2025, $1.1 million in Q3 2025, and $1.0 million in Q2 2025.